(redirected from neostigmine test)
Also found in: Thesaurus, Medical, Legal, Financial, Encyclopedia.


 (nē′ō-stĭg′mēn, -mĭn)
A cholinesterase inhibitor that is given in the form of a bromide salt, C12H19BrN2O2, or a methyl sulfate, C13H22N2O6S, used to treat myasthenia gravis and muscle atony and to reverse the effects of muscle relaxants after surgery.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Pharmacology) pharmacol a cholinergic drug which acts as a muscle stimulant and is used primarily to treat myasthenia gravis
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˌni oʊˈstɪg min, -mɪn)

a synthetic anticholinesterase, C12H19N2O2, used in the treatment of myasthenia gravis, glaucoma, and postoperative urinary bladder distention.
[1940–45; neo- + (physo)stigmine]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.neostigmine - a cholinergic drug (trade name Prostigmin) used to treat some ophthalmic conditions and to treat myasthenia gravis
anticholinesterase - a medicine that inhibits cholinesterase by combining with it and so has a cholinergic effect
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


n neostigmina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The present study has several limitations; for instance, seronegative MG patients included 85.5% of all patients and false negatives could not be defined using other diagnostic examinations, such as electromyogram, Neostigmine test, and Tensilon test.
The diagnostic criteria were as follows: [sup][10] Extraocular muscle weakness in one or both eyes, ptosis or double vision, and remission after rest and severe fatigue at the initiation of the symptoms; fatigue of the affected muscle with fatigue test; a positive neostigmine test; or abnormal repetitive nerve stimulation (RNS) electromyography with a minimum decrement of 15% in extremities muscles and 10% in facial muscles; or abnormal serum acetylcholine receptor antibody (AchRab) level.